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Abstract
Background: Patient and public involvement (PPI) is increasingly recognized as bring-
ing a range of benefits to clinical and health services research. Recent systematic re-
views have identified and synthesized many benefits (eg higher recruitment rates) and 
some costs (eg extra time need). Much of the literature focuses on PPI in long- term 
conditions rather than more acute health care in which the majority of microbiological 
research is undertaken.
Objectives: The aim was to identify the extent, quality and impact of PPI in antimicro-
bial drug development research. Objectives were to identify any relevant reporting of 
PPI in antimicrobial research; appraise the quality of reporting on PPI using recognized 
PPI reporting and critical appraisal tools; and extract and synthesize data on the im-
pact of PPI.
Search strategy: A systematic review was undertaken with a search strategy based on 
four word groups (PPI, patients, antimicrobial drug development and outcomes). Eight 
online databases were searched.
Inclusion criteria: English language publication, publication between 1996 and 2016 
and studies describing PPI in antimicrobial drug development research.
Main results: No studies were found through online searching that met the search 
strategy and inclusion criteria. One relevant protocol paper with a brief mention of PPI 
was identified through expert recommendation. Commentary papers recommending 
PPI were identified through website searching and expert opinion.
Discussion and conclusions: Despite strong policy guidance encouraging PPI at the 
international and national levels, and anecdotal accounts of PPI taking place, evidence 
for the extent, quality and impact of PPI in antimicrobial drug development research 
has not yet appeared in the peer- reviewed literature.
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1  | INTRODUCTION
1.1 | Background
Patient and public involvement (PPI) is increasingly recognized as bring-
ing a range of benefits to health services research. Recent structured1 
and systematic reviews2,3 have identified and synthesized many ben-
efits (eg improved study design, better participant information materi-
als, higher recruitment rates) and some costs and challenges (eg extra 
time need, risk of tokenism). Public involvement in research has been 
defined as “an active partnership between the public and research-
ers in the research process, rather than the use of people as ‘subjects’ 
of research.”1 Much of the literature focuses on PPI in long- term 
conditions (eg mental health, rheumatology) rather than more acute 
and laboratory settings such as those in which much microbiological 
research is undertaken. There is increasing concern in the field that 
PPI in research is often either not reported or reported inadequately.4 
Notably, the bibliography of PPI in research studies published by the 
UK National Institute for Health Research (NIHR) advisory group 
INVOLVE5 identifies no studies with a focus on PPI in antimicrobial 
drug development research (ie phase I, II and III studies carried out 
prior to regulatory agency approval or post- marketing studies).
Over the last decade, there has been increasing interest in PPI 
in drug development more generally, with a number of recent calls 
for action.6,7 More in- depth studies have included Duckenfield and 
Rangnekar’s report on patient group involvement in drug develop-
ment for chronic and progressive diseases, in particular two case 
studies on the involvement of patient groups in research on muscular 
sclerosis and Parkinson’s disease.8 Houyez discussed patient group 
involvement in drug development, with particular reference to AIDS 
patient organizations and activists.9 Patient advocacy groups are 
identified by Smits and Boon as important actors in pharmaceutical 
innovation.10 New PPI forums and initiatives have been established, 
such as the US Food and Drug Administration (FDA), Patient- Focused 
Drug Development initiative6 and the European Patients’ Academy on 
Therapeutic Innovation (EUPATI) launched in 2012 as a patient- led 
Innovative Medicines Initiative (IMI) project.11 EUPATI has published 
a useful paper of case reports on patient involvement in industry- led 
medicines development,12 but these all related to drugs for long- term 
conditions (including HIV/AIDS) rather than to antimicrobial drug de-
velopment for acute infections.
This distinction between PPI in long- term conditions and in an-
timicrobial drug development is potentially crucial as the opportuni-
ties for involvement and impact may vary considerably in the different 
settings. With many long- term conditions, there are well- established 
international, national and local patient groups that researchers can 
involve from the beginning of the research journey. In addition, clinical 
researchers in long- term conditions may have regular contact over a 
long period with relevant patients and carers, giving them ample oppor-
tunity to involve them early or at any subsequent stage of the research 
process. By contrast, there are few if any established patient groups 
for those with bacterial infections. Patients often experience acute 
bacterial infection as a one- off experience which is either successfully 
treated with antibiotics or may be fatal. If recovered, they may thus 
have less experiential knowledge of their condition. Moreover, such 
patients are unlikely to have any on- going identification as an “acute 
infection” patient, although they may identify with a chronic underly-
ing condition which predisposes to infection, such as cystic fibrosis or 
diabetes. Thus, the opportunities for involving patients in research on 
certain types of infection may be limited. What was unknown at the 
beginning of this study was the extent to which researchers were able 
to overcome these barriers and successfully involve patients in anti-
microbial drug development research. If and when these patients are 
involved in research, it was also not known whether their impact was 
similar or different to that reported in previous reviews on the involve-
ment of patients with long- term conditions in the research process.
As part of IMI- funded COMBACTE- MAGNET,13 a large pro-
gramme of research to develop new antimicrobial agents with a strong 
commitment to developing PPI, there was a requirement to establish 
the existing evidence base on relevant approaches to PPI that could 
be built on for the programme. Therefore, this rapid systematic review 
was conducted to provide an evidence base for the COMBACTE- 
MAGNET PPI initiative, in parallel with a rapid qualitative mapping of 
approaches to PPI in microbiological research which will be reported 
elsewhere.
1.2 | Aim and research questions
The aim of the research was to systematically review the microbiol-
ogy and PPI literature to identify the extent, quality and impact of PPI 
in antimicrobial drug development research. The research questions 
were as follows: (i) to what extent is PPI used in antimicrobial drug 
development research? (ii) in those studies where the use of PPI in 
antimicrobial research has been reported, what is the quality of re-
porting? and (iii) in those studies where the use of PPI in antimicrobial 
research has been reported, what is the impact of PPI?
2  | METHODS
2.1 | Design and search strategy
The design and search strategy followed expert guidance14 adapted 
the approach successfully used by one of the authors in a recent sys-
tematic review of PPI within surgical research15 Four relevant word 
groups were identified to capture terms relating to PPI, patients, an-
timicrobial drug development research and outcomes (Table 1). The 
search strategy sought to reflect the diversity in international termi-
nology relating both to PPI (eg involvement, engagement, participa-
tion) and to patients (eg citizens, public, users), but we recognized 
that at the time there was no consensus on appropriate terminology 
either in research or in the PPI field more generally. The outcome col-
umn relates to impacts on the research rather than to the ultimate 
health outcomes for patients which are unlikely to be identifiable in 
PPI research.
The searches were undertaken by a public health researcher (EB), 
experienced in systematic review methods, under the supervision of 
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the PPI lead (DE). Search terms were applied to titles, abstracts, key 
words and full texts. A pilot search was performed in MEDLINE to 
test the search strategy and refine the search terms before the full 
search of eight databases was undertaken. Databases searched were 
AMED, ASSIA, CINAHL, Cochrane Database of Systematic Reviews, 
EMBASE, ISI Web of Knowledge, MEDLINE and PsycINFO. The search 
strategy was adapted to reflect the structure and parameters of indi-
vidual databases. Documents retrieved for full text assessment were 
independently assessed for inclusion by DE to check the validity of 
inclusion and exclusion decisions. There were no differences in assess-
ment between the two reviewers, but if there had been, it was planned 
that these should be resolved through discussion.
All original studies of any study design published in English be-
tween 1996 and 2016 which described PPI in antimicrobial drug 
development research were included. Non- empirical commentary, 
guidance and opinion pieces were excluded.
In addition, the INVOLVE evidence library was searched, the jour-
nals Health Expectations and Research, Involvement and Engagement 
manually searched, and references and citations from non- empirical 
commentary papers on PPI and antimicrobial research were followed 
up. The EUPATI and PEW Charitable Trust (work programme on an-
tibiotics) websites were also searched. Experts in the fields of both 
PPI and antimicrobial research were contacted to identify any relevant 
papers.
2.2 | Ethical considerations
Although formal university ethical review was not required as this 
study did not involve collecting data from human participants, consid-
eration was given as to whether it raised any significant ethical issues. 
The subject matter (public involvement in research) was not a sensi-
tive issue, and authors of studies reporting microbiological research 
were unlikely to be vulnerable. PPI in research does not require review 
and approval, but ethical issues may arise, so ethical considerations as 
a data extraction field were included.
2.3 | Quality assessment
Previous reviews have commented on the difficulty of assessing the 
quality of articles reporting PPI in research.1,2 Only a relatively small 
number of papers report primary research on PPI; more usually, PPI 
is reported by researchers in relation to studies where the substan-
tive focus is on a health issue, and reporting on the PPI in the primary 
study is a secondary or subsequent concern. Given that the exten-
sive INVOLVE bibliography and the references included in previous 
structured and systematic reviews on PPI do not include any stud-
ies of PPI in microbiological research,1–3 it was deemed unlikely that 
there would be many eligible articles identified in this review, and 
that it would be unwise to set too demanding a quality threshold. 
We therefore followed the approach in Brett et al.2 and planned to 
include any study with a clear statement of aims, methods and re-
ported results. It was agreed that eligible studies would be quality 
appraised for PPI reporting according to an adapted version of the 
GRIPP checklist4 and the critical appraisal guidelines developed by 
Wright et al.16. All included studies were to be independently as-
sessed by EB and DE, and any cases of disagreement were to be 
resolved through discussion.
2.4 | Data extraction
Data were to be extracted under the following categories: publica-
tion details (author, year, title, journal, volume, number, pages); study 
details (aims, design, ethics, participants, results); PPI (aims, conceptu-
alization/terminology, number involved, ethical considerations, meth-
ods, results, impacts, strengths and limitations identified by authors); 
and strengths and limitations identified/other comments by reviewer.
2.5 | Data synthesis
We anticipated that most or all of any reports of PPI in microbiologi-




Advisory group* Citizen* Anti- bacterial Chang*
Patient advocacy Participant* Antibacterial Develop*
Patient engagement* Patient* Antibiotic* Impact*
Patient involvement Public* Anti- microbial* Improv*
Patient organi#ation* User* Antimicrobial* Participant information
Patient participation* Microbiolog* Priorit*




Patient panel* Research agenda*
PPI Research design*
User involvement Study design*
*Indicates truncation.
#Indicates alternative spelling allowed.
TABLE  1 Search terms
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case studies or other forms of qualitative reporting. Thus, a qualitative 
narrative thematic analysis was planned.17 Data from data extraction 
forms were to have been entered into NVivo 10 and independent 
analysis identifying key themes relating to the research question un-
dertaken by EB and DE.
2.6 | Patient and public involvement
As part of the wider literature on the potential benefits and im-
pact of PPI in research, there are an increasing number of published 
accounts of PPI in systematic review research.18,19 In principle, it 
would have been preferable to have had PPI in this review from the 
beginning. However, this rapid review was undertaken on a short 
timescale, while a microbiology patient panel was being established 
as part of our wider PPI initiative for the COMBACTE- MAGNET 
research programme. A pragmatic approach was therefore adopted. 
Potential panel members were alerted to the review and invited to 
contribute at the introductory microbiology patient panel meeting 
in October 2015. To facilitate the patients’ ability and confidence 
to contribute short educational inputs on subjects including re-
search methods were delivered by members of the research group. 
The main PPI on this review took place during a panel meeting in 
February 2016 where the limited findings of the review were dis-
cussed as a main agenda item, and panel members were invited 
to contribute to shaping the discussion section. Of the 16 panel 
members, seven chose to join the subgroup discussing the possi-
ble content of the systematic review discussion section. A number 
of the key points in the discussion section below emerged in this 
subgroup discussion (eg the recommendations in the penultimate 
paragraph of the discussion section) The draft paper was then sent 
to the subgroup to review and ensure that their points had been 
accurately included.
3  | RESULTS
Database searches identified 2388 potential article titles, with an 
additional 23 papers identified from contact with experts and hand 
searching, making a total of 2411 documents where title and abstract 
were screened for inclusion (Figure 1). After excluding 2307 for dupli-
cation or failing to meet inclusion criteria on first screening, 104 were 
obtained for full text assessment. Of these, 103 were then excluded 
for failing to meet the inclusion criteria, leaving one20 as the only arti-
cle included in the analysis (Box 1).
The key finding of this review is that there were no papers identi-
fied which focused on PPI in antimicrobial drug development research 
and only one in which there was a brief discussion of PPI, secondary to 
reporting on the main study. Moreover, this one paper was a protocol 
rather than a report of findings, and it was concerned with a new use 
of the drug rather than reporting pre- authorization or post- marketing 
F IGURE  1 Search results
Potenal documents retrieved from database 
search
AMED, CINAHL, MEDLINE, PsycINFO combined 
N=1837
ASSIA N=4
Cochrane Database of Systemac Reviews N=
244
EMBASE=294
Web of Science N=9
TOTAL N=2388
Addional documents idenfied from contact 
with experts and hand searching 
N=23
Documents screened for tle, abstract or 
duplicaon
N=2411
Documents excluded due to tle, abstract or 
duplicaon
N=2307
Documents retrieved for full text assessment
N=104
Documents excluded for failing to meet 
inclusion criteria
N=103
Full text documents included in this review
N=1
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PPI. Thus, compared to other areas of clinical and health services re-
search, there is very little evidence of the extent, quality or impact of 
PPI in antimicrobial drug development research.
Although a protocol paper, the amount of space allocated to the 
discussion of PPI (81 words) was similar to that found in papers in 
other areas of clinical research focused on the substance of a trial 
rather than specifically on PPI. Given the brevity of the PPI sec-
tion, it was not appropriate to apply either the GRIPP checklist or 
the quality appraisal guidelines developed by Wright et al. A GRIPP 
2 tool has been developed which offers a choice of checklists be-
tween a full version for PPI- focused studies and an abbreviated 
version for papers with brief PPI sections, but this has not yet been 
published.21
Due to the brevity of the PPI section in our one identified paper, 
we also followed up with queries to the lead author of the paper. He 
reported that eight to ten members of the SURF group were involved 
in initial discussions of the design of the trial, and one PPI member was 
recruited to the trial steering committee. She wrote the PPI section of 
the grant application and has advised and helped throughout the trial. 
Her role included writing the participant information sheets and when 
the study experienced some issues around consent; she wrote and un-
dertook a questionnaire survey and a small number of interviews with 
participants. She has presented with the lead author at a PPI trials con-
ference and will be drafting a specific report on PPI and the consent 
issues as well as the PPI section of the final report to NIHR (Thwaites, 
personal communication).
4  | DISCUSSION
It might be considered that finding only one relevant study briefly re-
porting PPI in antimicrobial drug development research is a negative 
and therefore a disappointing finding; however, negative findings of 
systematic reviews are important to publish as the failure to can lead 
to serious bias or omissions in the literature.22 This apparently nega-
tive finding is important in that it highlights a lack of reports of PPI in 
antimicrobial drug development research compared with some other 
areas of clinical and health services research. By contrast, there is a 
literature on PPI in other types of drug development research, in par-
ticular relating to drugs for long- term conditions such as Parkinson’s 
disease, multiple sclerosis and AIDS.6–8,10 Similarly, there is an in-
creasing body of literature on the contribution of PPI in other types 
of clinical trials23 and in experimental medicine research such as tissue 
banks.24 In principle, there is no reason why the types of PPI under-
taken and the contribution it has made in these areas should not be 
replicated in antimicrobial drug development research.
It is possible that our search missed some other examples of brief 
reports of PPI in antimicrobial research as such papers would not have 
included PPI or equivalent terms in the titles, abstracts or key words. 
However, as we also searched full texts, it is very unlikely that any 
papers with a substantive focus on PPI have been missed. There is 
also the possibility that the search terms used were insufficient to 
identify relevant literature, given the documented inconsistencies in 
PPI terminology and reporting.4,16 For example, our search did not 
include the term “consumer,” a term identified in a recent article de-
scribing the development and testing of a search filter for identifying 
PPI in health research.25 However, the proposed search filter was un-
published and therefore unavailable at the time this review was con-
ducted. Furthermore, consultations with experts in both the fields of 
PPI and antimicrobial research only uncovered one additional paper, 
suggesting that few, if any, have been missed.
There are two possible explanations for the findings. First, it may 
be that researchers have indeed undertaken PPI in antimicrobial drug 
development research, but have simply not written about it as they 
have focused their reporting on their substantive study findings and 
have had little incentive to report on the role of PPI. This may well be 
the case as some funders, in particular the UK National Institute for 
Health Research (NIHR), have for some years required researchers to 
include PPI in their research plans. As NIHR funds some microbiolog-
ical research, one would expect some PPI would have been under-
taken by UK microbiology researchers. Moreover, this finding would 
be consistent with the lack of reporting of PPI in other areas of health 
services research; the limited word counts allowed in many peer- 
reviewed clinical journals and lack of editorial requirement for such 
reporting, militates against the reporting of PPI. The second possibility 
is that (despite the requirements of some funders) few or no antimi-
crobial drug development researchers have included PPI in their work.
In either case, there would appear to be a lack of attention given to 
PPI by microbiology researchers. Even if PPI is being undertaken and 




Thwaites G, Auckland C, Barlow G et al. 
Adjunctive rifampicin to reduce early mortality 
from Staphylococcus aureus bacteraemia 
(ARREST): study protocol for a randomised 
controlled trial. Trials 2012; 13:241.
Study 
details
Protocol for randomized controlled trial to 
determine whether adjunctive rifampicin 
reduces all- cause mortality within 14 d and 
bacteriological failure or death within 12 wk 
from randomization.
PPI Trial developed with the Healthcare- 
associated Infection Service Users Research 
Forum (SURF). A SURF member will 
represent patients and the public on the Trial 
Steering Committee. Reports advice on 
inclusion of incapacitated adults and the 
application of the Mental Capacity Act, and 
the information provided to patients. Reports 
plans for assisting with dissemination to 





Explicit discussion of PPI activity and plans 
but the brevity of the PPI section makes it 
difficult to judge the extent, quality or impact 
of PPI.
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practice and problems encountered (and hopefully overcome) that re-
searchers are able to improve their PPI practice and so gain the maxi-
mum benefit from undertaking PPI. As our own patient panel pointed 
out in discussion, it is arguably unethical to involve people in research 
and not to report or acknowledge it.
Despite some methodological debates, the overwhelming body 
of evidence points to PPI bringing a range of benefits to clinical and 
health services research in general, and drug development research in 
particular. There has been a flurry of recent articles calling for more 
patient involvement in drug development,9,10 and although not anti-
microbial specific, the benefits they argue apply to antimicrobial re-
search. What we do not have is a specific evidence base around PPI 
in antimicrobial drug development research. But there is no reason to 
think that the benefits observed more generally in drug development 
would not also apply in antimicrobial drug development.
The major differences in antimicrobial drug development do not 
detract from the potential contribution of patients to the research pro-
cess. It is partly one of recruitment as patients with acute infection do 
not have established patient groups and do not usually have a long- 
term relationship with microbiology researchers; it is also that patients 
lived experience of their condition may not be as specific to the drug in 
development as for those patients with long- term conditions the drugs 
are directly targeting. Nonetheless, there is similar potential for patients 
with acute infection to contribute to the prioritization of research (eg 
around prioritizing interventions to control microbiological resistance) 
and the design of trials (eg around recruitment and retention).
Recently, a major IMI- funded study U- BIOPRED (Unbiased 
Biomarkers in Prediction of Respiratory Disease Outcomes) reported 
on its PPI.26 Interestingly, the authors note that this article was pro-
duced specifically in response to a comment by Catherine Stihler MEP 
at a European workshop on the need for researchers to communicate 
the value of meaningful patient involvement in EU projects. They 
therefore report their experience of patient involvement, but offer up 
key principles for success of patient involvement in other research: 
“involve early, involve deeply, have patients feedback on project prog-
ress, include patients in dissemination and help patients convey their 
own story.”26 In addition, they provide a comprehensive list of barri-
ers and difficulties for meaningful involvement, and suggestions from 
their experience on how to overcome these. Taken together, these 
principles and guidelines provide a template for other drug develop-
ment researchers. It is also notable that the principles and guidance 
are very similar to other advice coming from other IMI projects27 and 
more generic PPI reviews.1–3,5
In discussing the systematic review findings with our microbiol-
ogy patient panel, a number of potential solutions to the challenges of 
PPI in antimicrobial research were suggested by the panel members. 
These suggestions included that where microbiologists have clinical 
relationships with patients these need to be nurtured and built upon, 
in particular keeping in touch with patients post- treatment. Patient 
panels or advisory groups need to be established where none exist. 
Such groups need careful planning and skilled facilitation. In particular, 
the researchers need to be clear on the purposes of the group, what 
they want to get out of it. Researchers also need to think about the 
patients’ support and training needs. Providing some form of on- going 
education or learning can help keep people engaged; however, it is 
important for this to be led by the questions and learning needs of 
the group itself. Such education can help the group build up a level of 
expertize that enables them to contribute. Patient panel members em-
phasized the need for researchers to make panel members feel com-
fortable and safe to ask questions or make points; they need to feel 
there are no “wrong” or “silly” questions.
A recent study found pharmaceutical industry professionals to be 
positive but uncertain about PPI in medicines research and develop-
ment.28 In the light of the sparse findings of this systematic review, it 
is likely that microbiologists and other researchers involved in anti-
microbial drug development may have similar attitudes and levels of 
knowledge. Given the importance that funders such as IMI and NIHR 
now place on PPI, not to mention the ethical imperative expressed 
by patient groups for PPI to both take place and be reported, and the 
wealth of examples of the benefits of PPI and guidance from related 
areas of clinical and health services research on how to do it, the time 
has surely come for a sustained effort to develop and report PPI in 
antimicrobial drug development research.
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